Company Overview and News

 
Wabash National Corporation Announces Earnings Release Date

2018-04-16 globenewswire
LAFAYETTE, Ind., April 16, 2018 (GLOBE NEWSWIRE) -- Wabash National Corporation (NYSE:WNC) today announced it will conduct a conference call to review and discuss its first quarter results on Wednesday, May 2, 2018, at 10:00 a.m. EDT. Wabash National is scheduled to release its results on Tuesday, May 1, 2018, after the close of the financial markets.
Upvote Downvote

 
WNC / Wabash National Corp. DEF 14A

2018-04-06 sec.gov
UNITED STATES
Upvote Downvote

 
Is Wabash National (WNC) a Great Stock for Value Investors?

2018-04-03 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
Upvote Downvote

 
WNC / Wabash National Corp. / LSV ASSET MANAGEMENT - 3G (Passive Investment)

2018-02-13 sec.gov
SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: WABASH NATIONAL CORP CENTRAL INDEX KEY: 0000879526 STANDARD INDUSTRIAL CLASSIFICATION: TRUCK TRAILERS [3715] IRS NUMBER: 52-1375208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-41967 FILM NUMBER: BUSINESS ADDRESS: STREET 1: 1000 SAGAMORE PARKWAY SOUTH STREET 2: CITY: LAFAYETTE STATE: IN ZIP: 47905 BUSINESS PHONE: 7657715310 MAIL ADDRESS: STREET 1: 1000 SAGAMORE PARKW
Upvote Downvote

 
WNC / Wabash National Corp. / LSV ASSET MANAGEMENT - 3G (Passive Investment)

2018-02-13 sec.gov
SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: WABASH NATIONAL CORP CENTRAL INDEX KEY: 0000879526 STANDARD INDUSTRIAL CLASSIFICATION: TRUCK TRAILERS [3715] IRS NUMBER: 52-1375208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-41967 FILM NUMBER: BUSINESS ADDRESS: STREET 1: 1000 SAGAMORE PARKWAY SOUTH STREET 2: CITY: LAFAYETTE STATE: IN ZIP: 47905 BUSINESS PHONE: 7657715310 MAIL ADDRESS: STREET 1: 1000 SAGAMORE PARKW
Upvote Downvote

 
WNC / Wabash National Corp. FORM 8-K (Current Report)

2018-02-13 sec.gov
      SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 13, 2018   WABASH NATIONAL CORPORATION   (Exact name of registrant as specified in its charter)   Delaware   1-10883   52-1375208 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.
Upvote Downvote

 
Wabash National: Investors Should Just Stay The Course

2018-02-11 seekingalpha
The company's stock price has been pulled down by the broader market selloff, which I believe has created a buying opportunity.
Upvote Downvote

 
WNC / Wabash National Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
wabashnationalcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 6 )*       Name of issuer:  Wabash National Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  929566107     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)
Upvote Downvote

 
WNC / Wabash National Corp. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
wabashnationalcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 6 )*       Name of issuer:  Wabash National Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  929566107     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)
Upvote Downvote

 
WNC / Wabash National Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 1)*       WABASH NATIONAL CORP (Name of Issuer)   Common Stock (Title of Class of Securities)     929566107                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule
Upvote Downvote

 
WNC / Wabash National Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 1)*       WABASH NATIONAL CORP (Name of Issuer)   Common Stock (Title of Class of Securities)     929566107                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule
Upvote Downvote

 
WNC / Wabash National Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-02 fintel.io
Wabash National Corp. (NYSE:WNC) has 238 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 75,926,374 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., Dimensional Fund Advisors Lp, Royce & Associates LLC, JP Morgan Chase & Co, Lsv Asset Management, Vanguard Horizon Funds, Rothschild Asset Management Inc, Victory Capital Management Inc, and State Street Corp.
Upvote Downvote

 
WNC / Wabash National Corp. / VANGUARD HORIZON FUNDS - 3G/A (Passive Investment)

2018-02-02 sec.gov
wabashnationalcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.:1 )*       Name of issuer:  Wabash National Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  929566107     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)
Upvote Downvote

 
WNC / Wabash National Corp. / VANGUARD HORIZON FUNDS - 3G/A (Passive Investment)

2018-02-02 sec.gov
wabashnationalcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.:1 )*       Name of issuer:  Wabash National Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  929566107     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 929566107